LEGACYNCT01848561
A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 36 versions: 34 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 7 words
- Trial completed
- Primary completion date changed from estimate of Jun 2028 to Sep 30, 2026
- Study sites revised (512)
- Notable Primary and study completion dates: Jun 24, 2030 to Jun 2028
- Study sites: 511 to 512
- Minor Study sites: 510 to 511v34
- Minor Study sites: 513 to 510v33
- Notable Primary completion date: Apr 6, 2027 to Jun 24, 2030
- Study sites revised (513)
Show 28 earlier versionsHide 28 earlier versions
- Notable Primary completion date: Jun 24, 2030 to Apr 6, 2027
- Enrollment target: 5573 to 8250
- Study sites: 514 to 513
- Notable Primary and study completion dates: Apr 6, 2027 to Jun 24, 2030
- Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 8250 to confirmed 5573
- Study sites: 515 to 514
- Notable Enrollment target: 5450 to 8250
- Study sites revised (515)
- Notable Enrollment target: 8250 to 5450
- Study sites: 475 to 515
- Minor Study sites: 468 to 475v27
- Minor Study sites: 467 to 468v26
- Notable Eligibility criteria revised
- Study sites: 460 to 467
- Notable Eligibility criteria revised
- Study sites: 468 to 460
- Minor Study sites: 601 to 468v22
- Minor Primary and study completion dates: Apr 26, 2027 to Apr 6, 2027v21
- Minor Study sites: 599 to 601v19
- Minor Study sites: 587 to 599
- Primary and study completion dates: Apr 2027 to Apr 26, 2027
- Start date: Apr 2013 to Apr 29, 2013
- Minor Study sites: 585 to 587v17
- Minor Study sites: 568 to 585v16
- Minor Study sites: 560 to 568v15
- Minor Study sites: 555 to 560v14
- Minor Study sites: 553 to 555v13
- Notable Eligibility criteria expanded, about 4 words
- Study sites: 538 to 553
- Minor Study sites: 502 to 538v11
- Minor Study sites: 459 to 502v10
- Minor Study sites: 444 to 459v9
- Minor Study sites: 416 to 444v8
- Minor Study sites: 404 to 416v7
- Notable Eligibility criteria shortened, about 21 words
- Study sites: 290 to 404
- Secondary endpoints: details revised at 1 of 1 entry
- Minor Study sites: 241 to 290
- Interventions: Adalimumab (Biological), Immunomodulatory therapy (Drug) to not stated
- Minor Study sites: 29 to 241v4
- Minor Study sites: 11 to 29
- Start date: May 2013 to Apr 2013
- Minor Study sites: 1 to 11
- Start date: Apr 2013 to May 2013
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Evaluation of long term safety of Adalimumab in patients with moderately to severely active UC
Timeframe: 10 years observational period
Secondary (1)
Evaluation of long term effectiveness of Adalimumab in patients with moderately to severely active UC who have had an inadequate response to conventional therapy
Arms and interventions
Immunomodulatory Therapy
Patients who are being prescribed and treated with Immunomodulatory Therapy
Adalimumab (Humira) Treatment
Patients who are prescribed and treated with Adalimumab
Sites
512 sites in 21 countries
United States 170, Spain 69, Germany 63, Italy 29, United Kingdom 28, France 27, Canada 21, Belgium 15, Australia 14, Mexico 13, Greece 11, Israel 10, Netherlands 8, Ireland 7, Sweden 7, Austria 5, Croatia 5, Denmark 4, Puerto Rico 4, New Zealand 1, Norway 1